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Background:  Data  regarding  the  viremia  proﬁle  of  chikungunya  virus  (CHIKV)  infected  patients  especially
during  the  pre-febrile  period  is limited.
Objective:  To obtain  virological  kinetic  data  on  CHIKV  infections.
Study  design:  A  two-week  community  observation  for dengue  transmission  was  conducted  in Bandung,
Indonesia,  from  2005  to 2009.  Acute  specimens  from  non-dengue  febrile  patients  were  screened  by
pan-alphavirus  conventional  RT-PCR.  The  positives  were conﬁrmed  for CHIKV  RNA  by a  speciﬁc  RT-PCR
followed  by sequencing.  Simultaneously  these  specimens  were  also cultured  in Vero  cells  and  tested  for
anti-CHIK IgM MAC-ELISA.  All  the  available  serial  specimens,including  the pre-febrile  specimens,  from
conﬁrmed  CHIK  cases,  were  tested  by  virus  isolation,  RT-PCR,  qRT-PCR,  and  CHIK  IgM ELISA.
Results:  There  were  ﬁve  laboratory  conﬁrmed  CHIK  cases  identiﬁed  and  studied.  Among  these,  viremia
was  determined  to extend  from  as early  as  6 days  prior  to until  13  days  post  fever  onset.  Quantitative
RT-PCR  showed  viremia  peaked  at or near  onset  of illness.
Conclusion:  In  this  study, individuals  were  identiﬁed  with  viremia  prior  to fever onset  and  extending
beyond  the  febrile  phase.  This  extended  viremic  phase  has  the  potential  to impact  transmission  dynamics
and  thus  the public  health  response  to CHIK  outbreaks.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. BackgroundChikungunya virus (CHIKV), a positive-sense single stranded
NA alphavirus belonging to the family Togaviridae, is respon-
ible for explosive outbreaks of debilitating arthralgia in many
Abbreviations: CHIK, chikungunya; CHIKV, chikungunya virus; DEN, dengue;
ENV, dengue virus; RT-PCR, reverse transcriptase-polymerase chain reaction;
LISA, enzyme-linked immunosorbent assay.
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f Medicine, Universitas Padjadjaran, Jl. Eijkman No. 38 Bandung, West Java 40161,
ndonesia. Fax: +6222 2030776/2037823.
E-mail address: silvita.ﬁtri@gmail.com (S.F. Riswari).
ttp://dx.doi.org/10.1016/j.jcv.2015.11.017
386-6532/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tropical countries. As illness caused by CHIKV and dengue viruses
(DENV) are clinically undifferentiated, previously reported dengue
(DEN) outbreaks might actually have been caused by CHIKV [1].
Human-human transmission of both CHIKV and DENV involves
Aedes aegypti and Aedes albopictus mosquitoes, which can result
in co-circulation as high endemicity of both viruses has been con-
currently reported in the same area in Indonesia [2].
2. ObjectivesTo implement appropriate public health measures during out-
breaks, it is important to understand the possible duration of
transmission and the kinetics of CHIKV viremia. While there is
some information regarding how long the virus may  persist post
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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llness onset, there is limited knowledge on viremia prior to acute
pecimen acquisition [3–5]. For this reason, we conducted a ret-
ospective study using serial specimens from several observed
lusters collected during a DEN cluster study in Bandung, Indonesia
o obtain the complete viremia proﬁles of infected patients.
. Study design
The CHIKV retrospective cohort study was based on a DEN com-
unity cluster study conducted in Bandung, West Java, from 2005
o 2009 as described previously [6],in which blood specimens were
ollected to evaluate early dengue infection. Within 48 h of con-
rmation of a hospitalized dengue case (index case), community
lusters were selected. For each cluster, a maximum of twenty indi-
iduals aged 4 years or older living with the index case or living
ithin a 100 m radius from the index case’s home, were invited to
articipate in the study. A total of 1928 individuals in 97 clusters
ere enrolled in the study. After signing informed consent docu-
ents, demographic information, clinical data, and blood samples
ere taken on day of enrollment and participants were monitored
or 14 days for febrile episodes. Body temperature was measured
aily by a research nurse or physician and blood specimens were
aken every 3–4 days. Whenever fever occurred, another blood
pecimen was taken and the ﬁrst day of onset of fever was deﬁned
s day 0. DENV infection was conﬁrmed using IgM ELISA, reverse
ranscriptase-polymerase chain reaction (RT-PCR), and viral isola-
ion assays. The DEN community cluster study was approved by
he institutional review boards of the National Institute of Health
esearch and Development, Indonesian Ministry of Health, and
he U.S. Naval Medical Research Unit No. 2, Jakarta, Indonesia in
ompliance with all applicable Federal regulations governing the
rotection of human subjects.
CHIKV infection in non-DENV acute febrile specimens from
ll clusters was identiﬁed by a combination of laboratory assays.
cute specimens from 102 cases were initially screened by pan-
lphavirus conventional RT-PCR and those that tested positive were
onﬁrmed for CHIKV RNA by a speciﬁc RT-PCR targeting 1400 bp of
he E1 gene followed by sequencing [7–9]. In parallel with RT-PCR,
ll acute sera were cultured in Vero cells in 24-well culture plates.
ells that were positive for cytopathic effects (CPE) were exam-
ned by immunoﬂuorescent assay (IFA) using in-house generated
nti-CHIKV hyper-immune mouse ascitic ﬂuid (HMAF) antibodies
o conﬁrm that the CPE was caused by CHIKV [10,11]. All avail-
ble specimens from the 102 non-dengue febrile cases were tested
or anti-CHIK IgM using immunoglobulin M antibody capture ELISA
MAC-ELISA) [12]. To determine the antibody and virus kinetic pro-
ig. 1. Timeframe of chikungunya cases identiﬁed in two clusters. (A) cluster #40, (B) clu
nd  patient ID with # representing patients with recent infection prior to participation inal Virology 74 (2016) 61–65
ﬁles of CHIKV infection, all available serial specimens, including
pre-febrile specimens, of CHIKV positive cases (identiﬁed by RT-
PCR or culture) were tested by CHIK IgM ELISA, virus isolation,
and RT-PCR. In all CHIKV positive cases, CHIKV viral load was also
measured using real-time quantitative PCR (qRT-PCR) [13].
To determine the possibility of CHIKV infection among non-
febrile individuals in the cluster, paired sera (ﬁrst and last
collection) from individuals who  were never febrile during the
study period (n = 26) from community clusters were tested for
CHIKV IgM antibodies. First and last collection sera were compared
to identify seroconversion (two cases had no specimens available
for testing).
4. Results
Dengue was  conﬁrmed in 29 of 143 febrile cases (20.2%) from a
total of 97 community clusters with 1928 community volunteers in
the original study. The etiology of febrile illness for the remaining
114 cases could not be attributed to dengue infection. Upon per-
forming CHIKV testing on sera from these cases (102 cases with
specimens available), a total of 5 febrile CHIK cases from 2 clusters
(Cluster 40 and 61) were identiﬁed. In the ﬁrst cluster, 4 CHIKV
cases were identiﬁed: 2 were found positive by both RT-PCR and
serology, 1 by RT-PCR only, and 1 by serology only. In the sec-
ond cluster, one case was found positive (by RT-PCR) (Table 1).
All 4 cases conﬁrmed by alphavirus RT-PCR were also positive for
CPE and CHIKV IFA. Two  cases had their blood taken before day
0, and three starting from day 0 as they presented with fever on
the day of enrollment. Among the 5 symptomatic CHIKV cases,
clinical symptoms were moderate and non-speciﬁc with headache
(4/5), myalgia (4/5), nausea (4/5) cough (2/5), coryza (2/5), vomit-
ing (2/5), epigastric pain (1/5), gum bleeding (1/5), sore throat (1/5)
and arthralgia involving multiple joints (1/5). All symptomatic lab-
oratory conﬁrmed cases had fever with a duration of 1 to 3 days.
All cases recovered completely without sequelae and none were
hospitalized.
In two  cases (ID 4003 (Genbank accession KT175540) and 4010
(Genbank accession KT175541)), pre and post-febrile specimens
were available for testing. CHIKV qRT-PCR testing on serial speci-
mens from these cases indicated that viremia lasted for 11–13 days
(Table.1). Viremia was detected by a CHIKV-speciﬁc qRT-PCR at low
levels as early as 5 and 6 days before fever onset and peaked at 7 and
8 log10 PFU equivalents/mL on day 0 (fever onset). The viremia pro-
ﬁles of the 4 nucleic acid positive individuals are shown in Table 1
and Fig. 2.
ster #61. Symbol  representing positive qPCR, * representing positive IgM ELISA
 study. Gray color ( ) is day of fever.
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Table 1
Viremia and antibody proﬁles of symptomatic chikungunya cases.
Pat ID Sex/age CHIKV assay Days to the onset of fever
−9 −6 −5 −2 Day#0 (fever onset) 1 2 3 4 6 7 10 13
4001 Female/52 qRT (pfu equivalent/mL) . . . . 2,37E + 07 . . 7,62E + 01 . 3,69E + 01 3,25E + 01 1,02E + 01
CHIKV  isolate . . . . Pos . . Neg . Neg Neg Neg
Alphavirus RT PCR . . . . Pos . . Neg . Neg Neg Neg
CHIKV  IgM ELISA . . . . Neg . . Neg . Pos Pos Pos
4003  Male/35 qRT (pfu equivalent/mL) . . 5,47E + 01 1,79E + 03 1,06E + 07 5,08E + 06 . . 7,59E + 01 . 4,33E + 01 . .
CHIKV  isolate . . Neg Neg Pos Pos . . Neg . Neg . .
Alphavirus RT PCR . . Neg Neg Pos Pos . . Neg . Neg . .
CHIKV  IgM ELISA . . Neg Neg Neg Neg . . Pos . Pos . .
4010  Male/12 qRT (pfu equivalent/mL) Neg 1,57E + 01 . . 6,14E + 08 8,77E + 07 . . . . . . .
CHIKV  isolate Neg Neg . . Pos Pos . . . . . . .
Alphavirus RT PCR Neg Neg . . Pos Pos . . . . . . .
CHIKV  IgM ELISA Neg Neg . . Neg Neg . . . . . . .
6104  Male/16 qRT (pfu equivalent/mL) . . . . 3,98E + 06 . 4,68E + 05 . 4,05E + 02 . . . .
CHIKV  isolate . . . . Pos . Pos . Neg . . . .
Alphavirus RT PCR . . . . Pos . Pos . Neg . . . .
CHIKV  IgM ELISA . . . . Neg . Neg . Neg . . . .
4002  Male/12 qRT (pfu equivalent/mL) . . . . Neg . . . . . . . Neg
CHIKV  isolate . . . . Neg . . . . . . . Neg
Alphavirus RT PCR . . . . Neg . . . . . . . Neg
CHIKV  IgM ELISA . . . . Pos . . . . Pos . Pos Pos
Note: (.) = sample not available.
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Fig. 2. Viremia kinetics in four conﬁrmed chikungunya cases. The virem
Pan-alphavirus conventional RT-PCR was found to be less sen-
itive than the CHIKV-speciﬁc qRT-PCR (data unpublished). In this
tudy, the pan-alphavirus RT-PCR detected only specimens with
iremia at 5 log10 PFU equivalents/mL or higher. Using the CHIKV-
peciﬁc qRT-PCR, viral RNA was detected for 8 days (mean) after
nset compared with only 2 days (mean) for RT-PCR (Table 1). The
ensitivity between virus isolation and the conventional RT-PCR
ssay were comparable (Table 1). Virus isolation was  limited to
hose specimens drawn within the ﬁrst 2 days of illness onset.
Two cases demonstrated unexpected laboratory results. In one
ase (ID 4001(Genbank accesion KT175539)), CHIKV RNA persisted
or at least 13 days after illness and CHIK IgM antibodies were
ot detected until as late as 6 days after fever onset. Interestingly,
nother case (ID 4002) was already positive for CHIKV IgM anti-
ody at day 0, but was negative by RT-PCR and isolation. However,
ecause the patient was already febrile on day 0 and there was
o information available for fever status prior to this point, it is
onceivable that viremia had already subsided.
Genotype analysis of the CHIKV E1 gene fragment revealed
hat all isolates belonged to the Asian genotype and were closely
elated to the Bandung strains circulating in 2001–2008 [2] and
urabaya/Indonesia strains from 2010 to 2011 [14].
From clusters 40 and 61 (containing 33 total subjects, 26 with
aired specimens available), a total of four additional subjects had
 recent CHIKV infection as determined by the presence of IgM
ntibodies: one in cluster 40 and three in cluster 61 (Fig. 1). Apart
rom the index cases, no additional DEN infections were identiﬁed
mong subjects in these clusters during the two week observation
eriod (Fig. 2).
. Discussion
This study examined the viremia and antibody proﬁles of CHIKV
nfection based on archived specimens from an early dengue com-
unity study and revealed that CHIKV viremia preceded fever
nset by up to 6 days. A previous study that included collec-
ion of pre-illness specimens demonstrated viremia only a single
ay before illness in two cases [8]. The kinetics of CHIKV viremia
nd antibodies after illness observed in this study were sim-4 5 6 7 8 9 10 11 12 13 14
er (pfu equivalents/mL) during observation, day 0 = day of fever onset.
ilar to previous reports [3]. Additionally, high peak titers and
prolonged duration of viremia observed in this study are con-
sistent with earlier studies and could be an important factor
in facilitating the spread of CHIKV infection [3,13,15]. However,
unlike in animal models [16] or DENV studies [17], high CHIKV
viral loads did not seem to be correlated with increased disease
severity since no prolonged illnesses were observed with these
cases.
In this study, another 4 out of 26 subjects (15%) in clusters with
conﬁrmed CHIK infection had CHIKV-speciﬁc IgM antibodies from
day 1 of participation (Fig. 1), but fever was not reported during 14
days observation period. This suggests that chikungunya infection
had already occured in these communities prior to their partic-
ipation in this study. Chikungunya has previously been reported
as endemic in Bandung, Indonesia, with a yearly incidence rate
of 10.1 per 1000 persons [2]. These data suggest that chikungunya
should be considered in the differential diagnosis of acute febrile
cases.
The current study did have some limitations in that there was a
small number of CHIKV positive cases and only two conﬁrmed cases
with serial, pre-febrile specimens to study the full viremic proﬁle.
However, both cases revealed lengthy viremia before illness onset.
In addition, due to limited personnel and resources, daily serial
specimens were not collected as would have been ideal for a full
kinetic proﬁle. Compared with earlier reports on CHIKV infection
kinetics, where specimens were primarily post-fever onset [4], the
ﬁndings presented here reveal substantially extended viremia and
information regarding pre-fever viremia. This is of public health sig-
niﬁcance as patients with a prolonged viremic period and extensive
pre-febrile viremia may  have the potential to spread the virus long
before clinical presentation.
Earlier studies from Indonesia have reported the co-circulation
of DENV and CHIKV since both viruses utilize the same vector
species [14]. As no additional DENV cases were identiﬁed in these
two clusters with CHIKV positive subjects, the co-existence of
these two  viruses was likely of a low level in this community.
Furthermore, no CHIK cases were identiﬁed in the remaining 94
communities where DENV was  detected, strengthening this spec-
ulation.
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. Conclusions
In this study, CHIK cases identiﬁed in a DEN cluster study mani-
ested with a milder spectrum of clinical manifestations, with only
ne subject presenting with arthralgia, the hallmark of CHIKV infec-
ion. Physicians should consider CHIKV infection even in patients
ho present without polyarthralgias especially those who have
ecently traveled to CHIKV endemic areas. With the evidence for
engthy viremia found in this study, the CHIKV infectious period
ay  be greater than realized and should be considered as a factor
mpacting transmission in outbreak areas.
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